HealthLinx shares spike on ovarian cancer test data

Shares of Australia's HealthLinx shot up after the biotech announced that its diagnostic test for ovarian cancer outperformed the diagnostic tool now in use. Investigators said that OvPlex significantly reduced the number of diagnostic errors made in analyzing blood samples. Most women aren't diagnosed with ovarian cancer until the disease has progressed to a late stage, severely reducing their odds of surviving the disease for more than a few years. Story

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.